Don't blame trade openness for failure to grow manufacturing

A 1970s argument

Business Standard

Bt brinjal in Bangladesh calls for a policy review by India

The row over GM crops

India's Mars mission is well worth the cost

Igniting minds

A Congress in denial cedes space to a slick and energised BJP

Leaderless and lost

India must lead efforts for a climate change treaty

Weather at Warsaw

A ban on opinion polls would be an error of judgement

An undesirable move

Favourable global liquidity will keep investors happy

Samvat wishes

UPA's failure to reform shows up, starkly

No place for business

Kolkata's goodbye to Tendulkar defines bad taste

A farcical farewell

But all IT firms should address larger picture

Setback for Infosys

No recovery yet

India has contributed to Bangladesh's political turmoil

Abandoning Dhaka

New Delhi must now focus on restoring growth

Back to the government

RBI returns to normalcy, and a single instrument

An unambiguous signal

India cannot afford to boycott the Colombo meeting

The CHOGM connection

Why is it so hard for India's political leaders to explain what it is they want and plan to do? It is not as if Indian voters are stupid.

Editorial: Why can't India's politicians talk specifics?

For responsible private health care, improve public hospitals

Medical negligence

Behind the dimming lights in Gautam Buddh

Infant formula

Intermediation struggles

Clinical trials need better regulationThe pharmaceutical sector has been hit by one crisis after another. The latest is the Supreme Court directive to the Union health ministry to review 157 clinical trials approved by the Central Drugs Standard Control Organisation. On January 3, after allegations of irregularity in the approval process came up, the Supreme Court had banned clinical trials for all new chemical entities unless they were personally vetted and cleared by the health secretary. The recent directive comes after the government admitted that only five of the 162 approvals granted since then had been vetted by the health secretary. The Supreme Court has asked the ministry to re-examine the other 157 approvals by December 16.Frost & Sullivan has estimated that in 2010-11 the Indian clinical trial industry was worth $450 million (about Rs 2,800 crore at the current exchange rate). It is growing at 12 per cent annually and will cross the Rs 6,000-crore mark in 2016. However,

Page 242 - Editorial Comment